{"nctId":"NCT00079274","briefTitle":"Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer","startDateStruct":{"date":"2004-02"},"conditions":["Adenocarcinoma of the Colon","Stage III Colon Cancer"],"count":3397,"armGroups":[{"label":"Arm A (combination chemotherapy)","type":"EXPERIMENTAL","interventionNames":["Drug: oxaliplatin","Drug: leucovorin calcium","Drug: fluorouracil"]},{"label":"Arm B (combination chemotherapy)","type":"EXPERIMENTAL","interventionNames":["Drug: irinotecan hydrochloride","Drug: leucovorin calcium","Drug: fluorouracil"]},{"label":"Arm C (combination chemotherapy)","type":"EXPERIMENTAL","interventionNames":["Drug: irinotecan hydrochloride","Drug: oxaliplatin","Drug: leucovorin calcium","Drug: fluorouracil"]},{"label":"Arm D (combination chemotherapy, monoclonal antibody)","type":"EXPERIMENTAL","interventionNames":["Drug: oxaliplatin","Drug: leucovorin calcium","Drug: fluorouracil","Biological: cetuximab"]},{"label":"Arm E (combination chemotherapy, monoclonal antibody)","type":"EXPERIMENTAL","interventionNames":["Drug: irinotecan hydrochloride","Drug: leucovorin calcium","Drug: fluorouracil","Biological: cetuximab"]},{"label":"Arm F (combination chemotherapy, monoclonal antibody)","type":"EXPERIMENTAL","interventionNames":["Drug: irinotecan hydrochloride","Drug: oxaliplatin","Drug: leucovorin calcium","Drug: fluorouracil","Biological: cetuximab"]},{"label":"Arm G (Locally directed therapy)","type":"OTHER","interventionNames":["Drug: Locally Directed Therapy"]}],"interventions":[{"name":"irinotecan hydrochloride","otherNames":["Campto","Camptosar","CPT-11","irinotecan","U-101440E"]},{"name":"oxaliplatin","otherNames":["1-OHP","Dacotin","Dacplat","Eloxatin","L-OHP"]},{"name":"leucovorin calcium","otherNames":["CF","CFR","LV"]},{"name":"fluorouracil","otherNames":["5-fluorouracil","5-Fluracil","5-FU"]},{"name":"cetuximab","otherNames":["C225","C225 monoclonal antibody","IMC-C225","MOAB C225","monoclonal antibody C225"]},{"name":"Locally Directed Therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the colon\n\n  * Stage III disease\n  * No resected stage IV disease\n* No rectal cancer\n\n  * Gross inferior (caudad) margin of the primary tumor must be ≥ 12 cm from the anal verge by rigid proctoscopy\n* Stage III tumor must have been completely resected within the past 56 days\n\n  * Must have documented en bloc resection in patients with tumor adherence to adjacent structures\n  * Tumor-related obstructions and colonic perforation are allowed\n  * Tumor samples must be available\n* At least 1 pathologically confirmed positive lymph node\n\n  * No evidence of residual involved lymph node disease\n* Synchronous primary colon cancer allowed\n* No distant metastatic disease\n* Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2\n* Absolute neutrophil count ≥ 1,500/mm\\^3\n* Platelet count ≥ 100,000/mm\\^3\n* Hemoglobin ≥ 9 g/dL\n* Bilirubin ≤ 1.5 times upper limit of normal (ULN)\n* Creatinine ≤ 1.5 times ULN\n* No uncontrolled high blood pressure\n* No unstable angina\n* No symptomatic congestive heart failure\n* No myocardial infarction with the past 6 months\n* No New York Heart Association class III or IV heart disease\n* No symptomatic pulmonary fibrosis\n* No symptomatic interstitial pneumonitis\n* No prior allergic reaction (known sensitivity) to chimerized or murine monoclonal antibody therapy\n* No known allergy to platinum compounds\n* No documented presence of human anti-mouse antibodies (HAMA)\n* No active uncontrolled bacterial, viral, or systemic fungal infection\n* HIV negative\n* No clinically defined AIDS\n* Not pregnant or nursing\n* Negative pregnancy test\n* No men or women of childbearing potential who are unwilling to employ adequate contraception\n* No inadequately treated gastrointestinal bleeding\n* No ≥ grade 2 pre-existing peripheral sensory or motor neuropathy\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or lobular carcinoma in situ in 1 breast\n* No other concurrent medical condition that would preclude study participation\n* No concurrent biologic therapy\n* No prior chemotherapy for colon cancer\n* No other concurrent chemotherapy\n* No prior radiotherapy for colon cancer\n* No concurrent targeted agents\n* No prior agents directed against epidermal growth factor-receptor\n* No other concurrent anticancer therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease-free Survival (Arms A and D: Wild-type KRAS Patients)","description":"The primary endpoint for this study was to compare the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.\n\nDisease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.6","spread":null},{"groupId":"OG001","value":"71.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival (Arms A and D: Mutant KRAS Patients)","description":"A secondary endpoint for this study was to investigate the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.\n\nDisease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","spread":null},{"groupId":"OG001","value":"65.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Wild-type KRAS Patients)","description":"Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event free rates (percentage) are reported below for Wild-type KRAS Patients.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null},{"groupId":"OG001","value":"85.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Mutant KRAS Patients)","description":"Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event-free rates (percentage) are report below for mutant KRAS patients.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":null},{"groupId":"OG001","value":"82.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Wild-type KRAS Patients)","description":"The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"73.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)","description":"The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"72.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":93,"n":1378},"commonTop":["Diarrhea","Neutrophil count decreased","Paresthesias","Rash acneiform","Fatigue"]}}}